Assessment of the ExAC data set for the presence of individuals with pathogenic genotypes implicated in severe Mendelian pediatric disorders
暂无分享,去创建一个
Wyeth W Wasserman | Maja Tarailo-Graovac | Clara D M van Karnebeek | W. Wasserman | M. Tarailo-Graovac | C. V. van Karnebeek | J. Zhu | Jing Yun Alice Zhu | Allison Matthews | A. Matthews
[1] A. Baruchel,et al. Germline mutations of the CBL gene define a new genetic syndrome with predisposition to juvenile myelomonocytic leukaemia , 2010, Journal of Medical Genetics.
[2] K. Boycott,et al. Rare-disease genetics in the era of next-generation sequencing: discovery to translation , 2013, Nature Reviews Genetics.
[3] C. Tyler-Smith,et al. Deleterious- and disease-allele prevalence in healthy individuals: insights from current predictions, mutation databases, and population-scale resequencing. , 2012, American journal of human genetics.
[4] J. Ioannidis,et al. Clinical Genomics: From Pathogenicity Claims to Quantitative Risk Estimates. , 2016, JAMA.
[5] James Y. Zou. Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.
[6] Ricardo Villamarín-Salomón,et al. ClinVar: public archive of interpretations of clinically relevant variants , 2015, Nucleic Acids Res..
[7] H. Ida,et al. Gaucher disease types 1 and 3: Phenotypic characterization of large populations from the ICGG Gaucher Registry , 2015, American journal of hematology.
[8] Ryan W. Kim,et al. Carrier Testing for Severe Childhood Recessive Diseases by Next-Generation Sequencing , 2011, Science Translational Medicine.
[9] Brian T. Naughton,et al. Analysis of 589,306 genomes identifies individuals resilient to severe Mendelian childhood diseases , 2016, Nature Biotechnology.
[10] M. McCarthy,et al. Age-related clonal hematopoiesis associated with adverse outcomes. , 2014, The New England journal of medicine.
[11] J. Svendsen,et al. Integration of 60,000 exomes and ACMG guidelines question the role of Catecholaminergic Polymorphic Ventricular Tachycardia‐associated variants , 2017, Clinical genetics.
[12] Andrea Superti-Furga,et al. Exome Sequencing and the Management of Neurometabolic Disorders. , 2016, The New England journal of medicine.
[13] Joshua F. McMichael,et al. Age-related cancer mutations associated with clonal hematopoietic expansion , 2014, Nature Medicine.
[14] L. Vissers,et al. De novo nonsense mutations in ASXL1 cause Bohring-Opitz syndrome , 2011, Nature Genetics.
[15] R. Płoski,et al. M34T and V37I mutations in GJB2 associated hearing impairment: Evidence for pathogenicity and reduced penetrance , 2007, American journal of medical genetics. Part A.
[16] I. Screpanti,et al. Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype. , 2010, American journal of human genetics.
[17] Helga Thorvaldsdóttir,et al. Integrative Genomics Viewer , 2011, Nature Biotechnology.
[18] Bo Yuan,et al. Mutations in a novel gene with transmembrane domains underlie Usher syndrome type 3. , 2001, American journal of human genetics.
[19] L. Vissers,et al. Recurrent de novo mutations in PACS1 cause defective cranial-neural-crest migration and define a recognizable intellectual-disability syndrome. , 2012, American journal of human genetics.
[20] M. Loh,et al. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. , 2009, Blood.
[21] Glenn A. Maston,et al. A Standardized DNA Variant Scoring System for Pathogenicity Assessments in Mendelian Disorders , 2015, Human mutation.
[22] M. Hurles,et al. Clinical delineation of the PACS1‐related syndrome—Report on 19 patients , 2016, American journal of medical genetics. Part A.
[23] Peter Szolovits,et al. Genetic Misdiagnoses and the Potential for Health Disparities. , 2016, The New England journal of medicine.
[24] G. Rivard,et al. Gaucher disease: Variability in phenotype among siblings , 2004, Journal of Inherited Metabolic Disease.
[25] Gonçalo R. Abecasis,et al. The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..
[26] J. Casanova,et al. Guidelines for genetic studies in single patients: lessons from primary immunodeficiencies , 2014, The Journal of experimental medicine.
[27] R. Green,et al. Aggregate penetrance of genomic variants for actionable disorders in European and African Americans , 2016, Science Translational Medicine.
[28] Claire Redin,et al. XLID-causing mutations and associated genes challenged in light of data from large-scale human exome sequencing. , 2013, American journal of human genetics.
[29] Paul Shannon,et al. VariantAnnotation: a Bioconductor package for exploration and annotation of genetic variants , 2014, Bioinform..
[30] G. Scarano,et al. Two novel patients with Bohring–Opitz syndrome caused by de novo ASXL1 mutations , 2012, American journal of medical genetics. Part A.
[31] Magalie S Leduc,et al. Molecular findings among patients referred for clinical whole-exome sequencing. , 2014, JAMA.
[32] Beryl B. Cummings,et al. Pathogenic ASXL1 somatic variants in reference databases complicate germline variant interpretation for Bohring–Opitz Syndrome , 2017, Human mutation.
[33] C. Mason,et al. Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo , 2013, The Journal of experimental medicine.
[34] Bale,et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.
[35] G. Bejerano,et al. Systematic reanalysis of clinical exome data yields additional diagnoses: implications for providers , 2016, Genetics in Medicine.
[36] Gonçalo R. Abecasis,et al. The variant call format and VCFtools , 2011, Bioinform..
[37] S. Letovsky,et al. Exploring the landscape of pathogenic genetic variation in the ExAC population database: insights of relevance to variant classification , 2015, Genetics in Medicine.
[38] S. Gabriel,et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. , 2014, The New England journal of medicine.